Data spans seven presentations across both solid tumors and hematologic malignancies, providing updates on the potential benefit these therapies may bring to patients.  Data from the elacestrant plus ...

The research findings of experts from Roswell Park Comprehensive Cancer Center will be featured during the American Society ...

GLP-1 drugs may be linked to a lower risk of cancer progression, according to new research that will be presented next week at the American Society of Clinical Oncology’s annual meeting.

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that ten abstracts have been ...

GLP-1 medications were initially developed and prescribed to help manage blood sugar in people with Type 2 diabetes ...

Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of peptide ...

Accent Therapeutics, a clinical-stage biopharmaceutical company pioneering novel small molecule precision cancer therapies, ...

Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, announces the ...

A Phase I clinical trial is testing whether a tumor-targeting virus can help immunotherapy work more effectively against ...

A Cleveland Clinic study suggests GLP-1 weight loss drugs may help slow the spread of some obesity-related cancers.

Twenty-three abstracts will highlight the versatility and strength of Genmab’s portfolio and pipeline, including data from the comprehensive epcoritamab development program, including 4 oral ...

Data spans seven presentations across both solid tumors and hematologic malignancies, providing updates on the potential benefit these therapies may bring to patients. Data from the elacestrant ...